MacuCLEAR, Inc.   Report issue

For profit Phase 3
Founded: Plano TX United States (2006)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2009
NCT01013376
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

hydralazine (apresoline) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Geographic Atrophy (Phase 3)

Macular Degeneration (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1